Xgenera has developed a multi-cancer early diagnostic test that achieves 99% sensitivity and specificity across all cancer stages, enabling timely detection of cancer. This technology addresses the critical issue of late-stage cancer diagnoses, which significantly reduce survival rates, by providing a cost-effective solution for early intervention and treatment.
Funding
$650K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Late-stage cancer diagnoses significantly reduce survival rates, but current screening methods often fail to detect cancer early enough for effective intervention. Existing diagnostic tools may lack the sensitivity and specificity needed for reliable early detection across multiple cancer types.
Solution
Xgenera has developed a multi-cancer early diagnostic test designed to detect cancer at all stages with high accuracy. The test aims to address the challenge of late-stage diagnosis by providing a cost-effective method for early detection, when treatment is most effective. By identifying cancer early, Xgenera's technology seeks to improve patient outcomes and increase survival rates. The company focuses on making early cancer detection accessible, providing individuals with a greater chance of successful treatment and recovery.
Target Audience
The primary audience includes individuals at risk of cancer, healthcare providers seeking advanced diagnostic tools, and organizations focused on improving cancer screening and early detection programs.
Features
- Multi-cancer early diagnostic test
- High sensitivity (99%)
- High specificity (99%)
- Detects cancer at all stages
- Cost-effective solution